Goldman Sachs Raises BCR Target To $106

Goldman Sachs is raising its price target for C.R. Bard, Inc. BCR to $106 “due to our higher EPS estimates.” “Along with the FX changes, the increase in our 2011 BCR EPS estimate is largely the result of the timing of the accelerated share repurchase program that the company announced at the December analyst meeting,” Goldman Sachs writes. C.R. Bard, Inc. currently trades at $91.75.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst RatingsC.R. Bard Inc.Goldman SachsHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!